Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy) From Alzheimer Disease

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378 · see citing works

Second consensus statement on the diagnosis of multiple system atrophy

Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., Wood, N. W., Colosimo, C., Dürr, A., Fowler, C. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000324625.00404.15 · Cited by 3,140 · see citing works

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · see citing works

Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy

Conway, K. A., Lee, S., Rochet, J., Ding, T. T., Williamson, R. E., & Lansbury, P. T. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.2.571 · Cited by 1,543 · see citing works

Increased Expression of α-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis

Nemani, V. M., Lü, W., Berge‐Seidl, V., Nakamura, K., Onoa, B., Lee, M. K., Chaudhry, F. A., Nicoll, R. A., & Edwards, R. H. (2010) · Neuron · doi:10.1016/j.neuron.2009.12.023 · Cited by 1,051 · see citing works

Dementia with Lewy bodies

McKeith, I. G., Mintzer, J. E., Aarsland, D., Burn, D. J., Chiu, H. F. K., Cohen‐Mansfield, J., Dickson, D. W., Dubois, B., Duda, J. E., Feldman, H., et al. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00619-7 · Cited by 618 · see citing works

DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease

Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615 · see citing works

Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease

Tokuda, T., Salem, S. A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi, M. M., Locascio, J. J., Schlossmacher, M. G., & El-Agnaf, O. M. A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.08.024 · Cited by 425 · see citing works

Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration

Mollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T. F., Pepivani, I., Ng, J., Schulz-Schaeffer, W., Kretzschmar, H. A., McLean, P. J., et al. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.06.004 · Cited by 382 · see citing works

Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects

Borghi, R., Marchese, R., Negro, A., Marinelli, L., Forloni, G., Zaccheo, D., Abbruzzese, G., & Tabaton, M. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01153-8 · Cited by 363 · see citing works

Degeneration of Cardiac Sympathetic Nerve Begins in the Early Disease Process of Parkinson’s Disease

Orimo, S., Takahashi, A., Uchihara, T., Mori, F., Kakita, A., Wakabayashi, K., & Takahashi, H. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2006.00032.x · Cited by 243 · see citing works

Detection of elevated levels of soluble -synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies

Paleologou, K. E., Kragh, C. L., Mann, D. M. A., Salem, S. A., Al‐Shami, R., Allsop, D., Hassan, A. H. M., Jensen, P. H., & El‐Agnaf, O. M. A. (2008) · Brain · doi:10.1093/brain/awn349 · Cited by 225 · see citing works

Non-Aβ Component of Alzheimer's Disease Amyloid (NAC) Revisited

Culvenor, J. G., McLean, C., Cutt, S., Campbell, B. C. V., Maher, F., Jäkälä, P., Hartmann, T., Beyreuther, K. T., Masters, C. L., & Li, Q. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65220-0 · Cited by 176 · see citing works

Mitochondrial trafficking of APP and alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases

Devi, L., & Anandatheerthavarada, H. K. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.07.007 · Cited by 150 · see citing works

Differential levels of -synuclein, -amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease

Kasuga, K., Tokutake, T., Ishikawa, A., Uchiyama, T., Tokuda, T., Onodera, O., Nishizawa, M., & Ikeuchi, T. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.197483 · Cited by 142 · see citing works

In vivo visualization of -synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy

Kikuchi, A., Takeda, A., Okamura, N., Tashiro, M., Hasegawa, T., Furumoto, S., Kobayashi, M., Sugeno, N., Baba, T., Miki, Y., et al. (2010) · Brain · doi:10.1093/brain/awq091 · Cited by 113 · see citing works

α-Synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton

Esposito, A., Dohm, C. P., Kermer, P., Bähr, M., & Wouters, F. S. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.01.014 · Cited by 106 · see citing works

Tau phosphorylation increases in symptomatic mice overexpressing A30P α-synuclein

Frasier, M. A., Walzer, M., McCarthy, L., Magnuson, D. J., Lee, J. M., Haas, C. A., Kahle, P. J., & Wolozin, B. L. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.07.016 · Cited by 103 · see citing works

Cerebrospinal Fluid α-Synuclein Does Not Discriminate Between Dementia Disorders

Spies, P. E., Melis, R. J. F., Sjögren, M. J. C., Rikkert, M. G. M. O., & Verbeek, M. M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0955 · Cited by 93 · see citing works

CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease

Noguchi‐Shinohara, M., Tokuda, T., Yoshita, M., Kasai, T., Ono, K., Nakagawa, M., El‐Agnaf, O. M. A., & Yamada, M. (2008) · Brain Research · doi:10.1016/j.brainres.2008.11.055 · Cited by 92 · see citing works

Role of Synucleins in Alzheimer’s Disease

Crews, L. A., Tsigelny, I. F., Hashimoto, M., & Masliah, E. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9073-6 · Cited by 84 · see citing works

Cerebrospinal fluid tau, Aß, and phosphorylated tau protein for the diagnosis of Alzheimer's disease

Formichi, P., Battisti, C., Radi, E., & Federico, A. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20602 · Cited by 74 · see citing works

DJ‐1 is present in a large molecular complex in human brain tissue and interacts with α‐synuclein

Meulener, M. C., Graves, C. L., Sampathu, D. M., Armstrong‐Gold, C. E., Bonini, N. M., & Giasson, B. I. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03145.x · Cited by 71 · see citing works

Identification of novel proteins affected by rotenone in mitochondria of dopaminergic cells

Jin, J., Davis, J., Zhu, D. C., Kashima, D. T., Leroueil, M., Pan, C., Montine, K. S., & Zhang, J. (2007) · BMC Neuroscience · doi:10.1186/1471-2202-8-67 · Cited by 48 · see citing works

Cerebellar αsynuclein levels are decreased in Parkinson's disease and do not correlate with SNCA polymorphisms associated with disease in a Swedish material

Westerlund, M., Belin, A. C., Anvret, A., Håkansson, A. S., Nissbrandt, H., Lind, C., Sydow, O., Olson, L., & Galter, D. (2008) · The FASEB Journal · doi:10.1096/fj.08-110148 · Cited by 42 · see citing works

Fine epitope mapping of monoclonal antibodies specific to human α-synuclein

Choi, J., Park, H., Seong, Y.-M., Choi, E. Y., Min, B., & Rhim, H. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.11.058 · Cited by 5 · see citing works

Untitled work

Goodrum (2000) · doi:10.1002/(sici)1097-4547(20000215)59:4

α-synuclein in the pathophysiology of Alzheimer’s disease

Twohig, D., & Nielsen, H. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0320-x · Cited by 374 · see citing works

Recommendations to Standardize Preanalytical Confounding Factors in Alzheimer’s and Parkinson’s Disease Cerebrospinal Fluid Biomarkers: An Update

del Campo, M., Mollenhauer, B., Bertolotto, A., Engelborghs, S., Hampel, H., Simonsen, A. H., Kapaki, E., Kruse, N., Le Bastard, N., Lehmann, S., et al. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.46 · Cited by 343 · see citing works

Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies

Pagan, F., Hebron, M., Valadez, E. H., Torres-Yaghi, Y., Huang, X., Mills, R. R., Wilmarth, B. M., Howard, H., Dunn, C., Carlson, A., et al. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160867 · Cited by 265 · see citing works

Cerebrospinal fluid biomarkers in Parkinson disease

Parnetti, L., Castrioto, A., Chiasserini, D., Persichetti, E., Tambasco, N., El-Agnaf, O., & Calabresi, P. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.10 · Cited by 209 · see citing works

Fluid Biomarkers for Synaptic Dysfunction and Loss

Camporesi, E., Nilsson, J., Brinkmalm, A., Becker, B., Ashton, N. J., Blennow, K., & Zetterberg, H. (2020) · Biomarker Insights · doi:10.1177/1177271920950319 · Cited by 165 · see citing works

Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy

Wennström, M., Surova, Y., Hall, S., Nilsson, C., Minthon, L., Boström, F., Hansson, O., & Nielsen, H. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053250 · Cited by 141 · see citing works

α-Synuclein in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment

Korff, A., Liu, C., Ginghina, C., Shi, M., Zhang, J., & Initiative, F. T. A. D. N. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-130458 · Cited by 95 · see citing works

Increased CSF α‐synuclein levels in Alzheimer's disease: Correlation with tau levels

Slaets, S., Vanmechelen, E., Le Bastard, N., Decraemer, H., Vandijck, M., Martin, J., De Deyn, P. P., & Engelborghs, S. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.10.004 · Cited by 85 · see citing works

The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease

for the Dominantly Inherited Alzheimer Network (DIAN), Twohig, D., Rodriguez-Vieitez, E., Sando, S. B., Berge, G., Lauridsen, C., Møller, I., Grøntvedt, G. R., Bråthen, G., Patra, K., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0624-z · Cited by 68 · see citing works

Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders

Wang, Z.-Y., Han, Z.-M., Liu, Q.-F., Tang, W., Ye, K., & Yao, Y.-Y. (2015) · International Psychogeriatrics · doi:10.1017/s1041610215000447 · Cited by 39 · see citing works

Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study

Kruse, N., Persson, S., Alcolea, D., Bahl, J. M. C., Baldeiras, I., Capello, E., Chiasserini, D., Bocchio Chiavetto, L., Emersic, A., Engelborghs, S., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.05.003 · Cited by 38 · see citing works

Alpha‐synuclein <scp>RT</scp> ‐Qu <scp>IC</scp> in the <scp>CSF</scp> of patients with alpha‐synucleinopathies

Fairfoul, G., McGuire, L. I., Pal, S., Ironside, J. W., Neumann, J., Christie, S., Joachim, C., Esiri, M., Evetts, S. G., Rolinski, M., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.338 · Cited by 608 · see citing works

The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies

Van der Perren, A., Gelders, G., Fenyi, A., Bousset, L., Brito, F., Peelaerts, W., Van den Haute, C., Gentleman, S., Melki, R., & Baekelandt, V. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02157-3 · Cited by 277 · see citing works

Parkinson’s disease and multiple system atrophy patient iPSC-derived oligodendrocytes exhibit alpha-synuclein–induced changes in maturation and immune reactive properties

Azevedo, C., Teku, G., Pomeshchik, Y., Reyes, J. F., Chumarina, M., Russ, K., Savchenko, E., Hammarberg, A., Lamas, N. J., Collin, A., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111405119 · Cited by 48 · see citing works

Alpha‐Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies

Singer, W., Schmeichel, A. M., Shahnawaz, M., Schmelzer, J. D., Boeve, B. F., Sletten, D. M., Gehrking, T. L., Gehrking, J. A., Olson, A. D., Savica, R., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25824 · Cited by 131 · see citing works

Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy

Shahnawaz, M., Mukherjee, A., Pritzkow, S., Mendez, N., Rabadia, P., Liu, X., Hu, B., Schmeichel, A., Singer, W., Wu, G., et al. (2020) · Nature · doi:10.1038/s41586-020-1984-7 · Cited by 820 · see citing works